MIR186

Summary

MIR186 (microRNA 186, HGNC:31557) is a microRNA gene on chromosome 1p31.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406962 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31557
Approved symbol	MIR186
Name	microRNA 186
Location	1p31.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-186
Ensembl gene	ENSG00000207721
Ensembl biotype	miRNA
Entrez	406962
RNAcentral	URS000059EAAC — miRNA, 86 nt, 15 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384988

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384988 — 1 exons

Exon	Start	End
ENSE00001499995	71067631	71067716

Expression profiles

Bgee: expression breadth ubiquitous, 123 present calls, max score 98.47.

Top tissues by expression

123 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	98.47	gold quality
endometrium	UBERON:0001295	97.91	gold quality
adrenal tissue	UBERON:0018303	96.57	gold quality
vermiform appendix	UBERON:0001154	95.87	gold quality
right coronary artery	UBERON:0001625	95.37	gold quality
body of uterus	UBERON:0009853	95.31	gold quality
right ovary	UBERON:0002118	94.98	gold quality
uterus	UBERON:0000995	94.91	gold quality
right uterine tube	UBERON:0001302	94.60	gold quality
left ovary	UBERON:0002119	94.51	gold quality
ovary	UBERON:0000992	94.32	gold quality
duodenum	UBERON:0002114	94.13	gold quality
descending thoracic aorta	UBERON:0002345	94.12	gold quality
left uterine tube	UBERON:0001303	94.00	gold quality
rectum	UBERON:0001052	93.89	gold quality
fundus of stomach	UBERON:0001160	93.61	gold quality
body of pancreas	UBERON:0001150	93.37	gold quality
stomach	UBERON:0000945	92.69	gold quality
endocervix	UBERON:0000458	92.66	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	92.27	gold quality
right lung	UBERON:0002167	92.17	gold quality
body of stomach	UBERON:0001161	92.08	gold quality
myometrium	UBERON:0001296	92.00	gold quality
thoracic aorta	UBERON:0001515	91.99	gold quality
ascending aorta	UBERON:0001496	91.74	gold quality
small intestine	UBERON:0002108	91.58	gold quality
fallopian tube	UBERON:0003889	91.47	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.41	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.40	gold quality
lower esophagus	UBERON:0013473	91.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.97

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• increased expression of miR-186 and miR-150 in cancer epithelial cells decreases P2X7 mRNA by activation of miR-186 and miR-150 instability target sites located at the 3’-UTR-P2X7 (PMID:18682393)
• miR-186 showed dysregulation in myocardial infarction or fetal hearts when compared to healthy adults. (PMID:20075508)
• This study identified both PTTG1 and miR-186 as potential anti-invasion targets for therapeutic intervention in non-small cell lung cancer . (PMID:23671127)
• Aberrant expression levels of miR-186, miR-494 and miR-3651 in whole blood samples of oral squamous cell carcinoma are associated with malignancy. (PMID:24452363)
• Serum microRNAs were identified as cardiovascular risk factors in dyslipidemia. (PMID:24461990)
• Data indicate that Rho-associated protein kinase 1 (ROCK1) was inversely correlated with miR-186 expression in non-small cell lung cancer (NSCLC). (PMID:24894676)
• miR-186 targets the 3’ UTR of Glut1, and its overexpression results in the degradation of Glut1 mRNA, which eventually reduces the level of Glut1 protein. miR-186 regulates glucose uptake and lactate production which is mediated by Glut1. (PMID:24935378)
• Differentiation of human induced pluripotent stem cells into insulin-like cell clusters with miR-186 and miR-375 by using chemical transfection. (PMID:25059983)
• Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells. (PMID:25139266)
• Plasma microRNA-186 was correlated with degress of proteinuria in patients with focal segmental glomerulosclerosis. (PMID:25218681)
• These findings suggest that miR-186 over-expression contributes to the invasive potential of pancreatic ductal adenocarcinoma, likely via suppression of NR5A2, thereby leading to a poor prognosis (PMID:25742499)
• the EMT phenotype was detected in cisplatin-resistant ovarian cancer tissues and cell lines, and correlated with decreased miR-186 expression, increased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (PMID:25867064)
• CRNDE played an oncogenic role of glioma stem cells through the negative regulation of miR-186. (PMID:26231038)
• Our data first time identified miR-186 as the upstream regulator of NSBP1 (PMID:26290438)
• Down-regulation of miR-186 contributes to podocytes apoptosis in membranous nephropathy. (PMID:26382839)
• This study has identified PPM1B and miR-186 as potential diagnostic markers in bladder cancer. Promotion of PPM1B and suppression of miR-186 may offer effective therapeutic strategies in the treatment of bladder cancer. (PMID:26494000)
• miR-186 has a suppressive role in esophageal squamous cell carcinoma progression via SKP2-mediated pathway (PMID:26568291)
• The results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-pi. (PMID:26626440)
• Our collective results clearly indicate that miR-186 functions as a tumor suppressor in MM, supporting its potential as a therapeutic target for the disease. (PMID:26679605)
• Results show that plasma levels of miR-19b-3p, miR-134-5p and miR-186-5p were significantly increased in early stage of acute myocardial infarction. (PMID:26939053)
• Study suggests that miR-186 down-regulation is a frequent event and predicts poor prognosis in de novo AML patients. (PMID:27012040)
• miR186 strongly inhibits cell motility, invasive, soft-agar colony formation, 3D culture growth and vasculogenic mimicry (VM) formation capacity, as well as the epithelial-to-mesenchymal transition (EMT) process by downregulation of its target Twist1. (PMID:27121312)
• MicroRNA-186 promotes macrophage lipid accumulation and pro-inflammatory cytokine secretion by targeting cystathionine gamma-lyase in THP-1 macrophages (PMID:27205869)
• In human prostate cancer specimens, mPGES-1 was over-expressed in tumors with high Gleason score, elevated expression of VEGF and HIF-1alpha, high microvessel density and decreased expression of Dicer, miR15a and miR-186. (PMID:27322147)
• Our findings suggest that attenuated expression of miR-185 and miR-186 may be responsible for collagen V overexpression during idiopathic pulmonary fibrosis (PMID:27392970)
• Study found miR-186 expression significantly decreased in lung cancer tissues and cells and MAP3K2 expression increased in the same cancer tissues. Also, results confirmed that MAP3K2 is a target gene of miR-186 and both expression correlated with prognosis. (PMID:27498924)
• our study demonstrated that miR-186 regulates the chemoresistance of NSCLC cells by modulating the MAPT expression level both in vitro and in vivo. (PMID:27714074)
• miR-186 affects the proliferation, invasion and migration of human gastric cancer (GC) by inhibition of Twist1, and could be a tumor suppressor in GC development. Thus, miR-186 may be served as a candidate prognostic biomarker and target for new therapies in human gastric cancer. (PMID:27835599)
• MiR-186-5p is a novel tumor suppressor microRNA that functions to inhibit tumorigenesis of glioblastoma multiforme both in vitro and in vivo. (PMID:28213656)
• Long non-coding RNA TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. (PMID:28302487)
• Study shows that miR186 is down-regulated in non-small cell lung cancer (NSCLC) tissues and reduces invasion ability of NSCLC cell lines by directly targeting cdc42 and modulating epithelial-mesenchymal transition process which effects cell adhesion. According to these findings, miR-186 is proposed to be one of the tumor-suppressors for NSCLC. (PMID:28317368)
• PVT1 overexpression increased the expression of Atg7 and Beclin1 by targeting miR-186, which induced protective autophagy, thus promoting glioma vascular endothelial cell proliferation, migration, and angiogenesis. Therefore, PVT1 and miR-186 can provide new therapeutic targets for future anti-angiogenic treatment of glioma (PMID:28351322)
• MiR-186-5p overexpression blocked the oncogenic effects of XIST on cell proliferation and invasion, suggesting that the effects of XIST on non-small cell lung cancer growth and invasion are partially mediated by miR-186-5p. (PMID:28448993)
• Altered expression of miR-494, miR-3651 and miR-186 appears to be associated with the recurrence of oral squamous cell carcinoma (OSCC). The present study may form the basis for establishing a blood test as a minimally invasive method for the detection of the recurrence of OSCC. (PMID:28498442)
• miR-186-5p expression promotes colorectal cancer pathogenesis by regulating tumour suppressor FAM134B (PMID:28549913)
• miR-185 was significantly downregulated in RCC tissues and cell lines. SENP1 was a direct target of miR-186, and SENP1 mRNA expression was reversely correlated with miR-186 in RCC tissues. (PMID:28550686)
• present study identifies the crucial regulation of hsa_circ_0010729 on vascular endothelial cell proliferation and apoptosis via targeting miR-186/HIF-1alpha axis (PMID:28571741)
• it was identified that plasmacytoma variant translocation 1 regulated the expression of the miR-186-5p target gene, yes-associated protein 1. Taken together, plasmacytoma variant translocation 1 served as an endogenous sponge for miR-186-5p to reduce its inhibiting effect on yes-associated protein 1 and thus promoted the tumorigenesis of hepatocellular carcinoma (PMID:28656879)
• Expression levels of HULC are positively correlated with those of HMGA2 in clinical hepatocellular carcinoma tissues. Data suggest that HULC up-regulates expression of HMGA2 in hepatocytes and enhances hepatocarcinogenesis; microRNA-186 inhibits HMGA2 expression by targeting the 3prime-untranslated region of HMGA2 mRNA. (HULC = HULC long non-coding RNA HULC; HMGA2 = high mobility group AT-hook 2) (PMID:28765279)
• Data show that miR-186 was found to directly target Yin Yang 1 (YY1). (PMID:29060934)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir186	ENSMUSG00000065431
rattus_norvegicus	Mir186	ENSRNOG00000035617

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.